The examples you have shown had marginal results in the small studies to start with. Find me an example of where there has been 10 times outperformance i.e 8% vs 88% survival and then it failed in the larger trial. The point I have repeated a few times now is that the bar is very low, atm. I would argue there are almost no treatments for ARDS as even the ventilators have such a low success rate that it is effectively a death sentence.
Nothing is guaranteed. If you want the guaranteed results at the end of the rainbow, they have huge premiums.
Ann: 83% Survival in COVID-19 ARDS Patients with Remestemcel-L, page-501
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$2.39 |
Change
0.105(4.61%) |
Mkt cap ! $2.995B | |||
| Open | High | Low | Value | Volume |
| $2.31 | $2.39 | $2.30 | $5.104M | 2.168M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 28 | 36554 | $2.38 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.39 | 66758 | 22 |
View Market Depth
| Last trade - 10.59am 23/07/2025 (20 minute delay) ? |
| MSB (ASX) Chart |